We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+2.81%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$628M
AUM Growth
-$105M
Cap. Flow
-$132M
Cap. Flow %
-21%
Top 10 Hldgs %
31.66%
Holding
141
New
23
Increased
28
Reduced
42
Closed
26

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$23.5M
2
NVMI
Nova
NVMI
+$11.1M
3
APLS
Apellis Pharmaceuticals
APLS
+$7.99M
4
VKTX icon
Viking Therapeutics
VKTX
+$7.81M
5
CHKP icon
Check Point Software Technologies
CHKP
+$7.36M

Top Sells

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$28.3M
2
CYTK icon
Cytokinetics
CYTK
+$8.91M
3
CRM icon
Salesforce
CRM
+$8.64M
4
PRAX icon
Praxis Precision Medicines
PRAX
+$7.08M
5
ASML icon
ASML
ASML
+$6.31M

Sector Composition

Rank Sector Weight
1 Healthcare 70%
2 Technology 19.18%
3 Consumer Discretionary 3.53%
4 Communication Services 2.96%
5 Utilities 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$40.8B
$38.4M 6.11%
2,130,216
+1,340,800
+170% +$23.5M
SNY icon
2
Sanofi
SNY
$103B
$23.6M 3.76%
409,515
-40,000
-9% -$2.16M
BBIO icon
3
BridgeBio Pharma
BBIO
$15.7B
$21.5M 3.41%
842,644
-67,426
-7% -$1.77M
SNDX icon
4
Syndax Pharmaceuticals
SNDX
$1.69B
$19.9M 3.17%
1,034,846
+212,799
+26% +$4.4M
AMZN icon
5
Amazon
AMZN
$2.92T
$19.7M 3.13%
105,607
+4,175
+4% +$762K
META icon
6
Meta Platforms (Facebook)
META
$1.42T
$16.8M 2.67%
29,316
-4,123
-12% -$2.12M
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.57B
$15.7M 2.5%
125,846
+42,187
+50% +$5.83M
AZN icon
8
AstraZeneca
AZN
$263B
$14.8M 2.36%
95,030
– –
MSFT icon
9
Microsoft
MSFT
$3.45T
$14.4M 2.29%
33,427
+500
+2% +$214K
CLDX icon
10
Celldex Therapeutics
CLDX
$2.99B
$14.2M 2.27%
419,103
+109,838
+36% +$4.19M
AAPL icon
11
Apple
AAPL
$4.54T
$14.2M 2.26%
60,847
-653
-1% -$146K
NICE icon
12
Nice
NICE
$5.79B
$13.6M 2.17%
78,361
-3,100
-4% -$532K
KURA icon
13
Kura Oncology
KURA
$800M
$11.9M 1.9%
610,087
-739
-0.1% -$15K
CYTK icon
14
Cytokinetics
CYTK
$10.5B
$11.9M 1.89%
225,021
-159,903
-42% -$8.91M
LLY icon
15
Eli Lilly
LLY
$1.02T
$11.7M 1.86%
13,190
– –
JNJ icon
16
Johnson & Johnson
JNJ
$618B
$11.3M 1.8%
69,831
– –
RARE icon
17
Ultragenyx Pharmaceutical
RARE
$2.45B
$10.9M 1.73%
195,349
-98,483
-34% -$5.02M
NVMI
18
Nova
NVMI
$12.4B
$10.8M 1.72%
+51,960
New +$11.1M
NVO
19
Novo Nordisk
NVO
$208B
$9.3M 1.48%
78,080
– –
TSEM icon
20
Tower Semiconductor
TSEM
$24.8B
$9.27M 1.48%
209,441
+59,841
+40% +$2.45M
PRAX icon
21
Praxis Precision Medicines
PRAX
$8.58B
$8.76M 1.39%
152,307
-131,117
-46% -$7.08M
VKTX icon
22
Viking Therapeutics
VKTX
$3.7B
$8.42M 1.34%
+133,066
New +$7.81M
HELP
23
Cybin Inc
HELP
$485M
$8.3M 1.32%
933,225
+260,030
+39% +$2.57M
IMTX icon
24
Immatics
IMTX
$1.18B
$8.23M 1.31%
721,111
-10,000
-1% -$118K
PHVS icon
25
Pharvaris
PHVS
$2.28B
$8.14M 1.29%
439,292
+36,027
+9% +$658K
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2024 Portfolio in Review

As of Q3 2024, Sphera Funds Management held 141 positions worth $628M, down 14% from $733M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Sphera Funds Management withdrew a net $132M in Q3 2024, closing 26 positions and reducing 42 holdings. Its most notable exit was Salesforce, an estimated $8.64M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 59% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Sphera Funds Management opened a new position in Nova worth $10.8M.

  • Sphera Funds Management's largest Q3 2024 buy was Nova: 51,960 shares worth $10.8M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q3 2024, an estimated $23.5M increase.
  • Sphera Funds Management's biggest Q3 2024 reduction was Broadcom, cutting an estimated $28.3M.
  • Sphera Funds Management fully exited Salesforce in Q3 2024, selling an estimated $8.64M.
  • Sphera Funds Management's ten largest holdings make up 32% of its $628M portfolio in Q3 2024.
  • Sphera Funds Management opened 23 new positions and closed 26 in Q3 2024.
  • Sphera Funds Management's portfolio value fell 14% quarter-over-quarter to $628M.

Based on Sphera Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.